title: Growth Hormone Treatment Increases Plasma Irisin Concentration in Patients with Turner Syndrome.
abstract: Irisin (Ir) deficiency may be a contributing factor in metabolic disease. This study aimed to investigate the effect of supraphysiological doses of recombinant human growth hormone (rhGH) on Ir plasma concentration in relation to metabolic disorders, including obesity and other components of metabolic syndrome. We studied 36 girls with Turner syndrome (mean age 8.2 years) treated with rhGH (0.05 mg/kg/day). Anthropometric data and fasting blood levels [e. g., Ir, insulin, glucose, glycated hemoglobin (HbA1c), IGF-1, IGFBP-3, cholesterol, insulin resistance (HOMA-IR), and β-cell function (HOMA-β)] were analyzed prior to and following rhGH therapy [mean (SD) follow-up of 1.47 (0.89) years]. Insulin sensitivity (Matsuda index) was calculated before and after the glucose load. Following rhGH therapy, an increase in IGF-1 [mean (SD) of 119.40 (62.47) ng/ml to 439.08 (209.91) ng/ml, p=0.000], Ir [2.10 (1.03) μg/ml to 2.48 (0.78) μg/ml, p=0.036], HOMA-IR [median (IQR) of 0.64 (0.45-1.30) to 0.92 (0.67-2.36), p=0.0206], and HOMA-β values [45.00 (27.69-72.00) to 81.53 (51.43-132.00), p=0.0447] were observed. Multiple regression analysis yielded no associations between Ir and metabolic and hormonal parameters before rhGH treatment; however, on rhGH, the model (R2=0.56, adjusted R2=0.45) showed positive associations between Ir and IGF-1 standard deviation score and HbA1c, and negative associations between Ir and fasting blood glucose, HDL-cholesterol, and triglycerides. Despite manifestation of insulin resistance, rhGH application had a positive effect on Ir regulation, and restored physiological conditions of lipid and glucose metabolism.
authors.affiliation: Department of Endocrinology and Diabetology for Children and Adolescents, Wroclaw Medical University, Poland.
authors.forename: B
authors.initials: B
authors.lastname: Wikiera
authors.affiliation: Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland.
authors.forename: K
authors.initials: K
authors.lastname: Zawadzka
authors.affiliation: Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland.
authors.forename: Ł
authors.initials: Ł
authors.lastname: Łaczmański
authors.affiliation: Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland.
authors.forename: N
authors.initials: N
authors.lastname: Słoka
authors.affiliation: Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Bolanowski
authors.affiliation: Department of Endocrinology and Diabetology for Children and Adolescents, Wroclaw Medical University, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Basiak
authors.affiliation: Department of Endocrinology and Diabetology for Children and Adolescents, Wroclaw Medical University, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Noczyńska
authors.affiliation: Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Daroszewski
mesh_terms: D000293:Adolescent; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D005215:Fasting / Q000097:blood; D005260:Female; D005353:Fibronectins / Q000097:blood*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007621:Karyotyping; D015999:Multivariate Analysis; D012044:Regression Analysis; D014424:Turner Syndrome / Q000097:blood* / Q000188:drug therapy*
chemical_list: D001786:Blood Glucose; C577593:FNDC5 protein, human; D005353:Fibronectins; D007328:Insulin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I